Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Acquires $44,600.00 in Stock

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Mihael Hristos Polymeropoulos acquired 10,000 shares of the business’s stock in a transaction dated Tuesday, February 25th. The stock was acquired at an average price of $4.46 per share, for a total transaction of $44,600.00. Following the completion of the transaction, the chief executive officer now owns 2,331,730 shares in the company, valued at approximately $10,399,515.80. The trade was a 0.43 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Vanda Pharmaceuticals Trading Down 0.2 %

Shares of NASDAQ:VNDA opened at $4.70 on Friday. The stock has a fifty day simple moving average of $4.59 and a two-hundred day simple moving average of $4.80. The stock has a market capitalization of $274.09 million, a price-to-earnings ratio of -14.69 and a beta of 0.74. Vanda Pharmaceuticals Inc. has a 12-month low of $3.71 and a 12-month high of $6.75.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.06. The business had revenue of $53.19 million during the quarter, compared to analysts’ expectations of $51.00 million. Vanda Pharmaceuticals had a negative return on equity of 3.49% and a negative net margin of 9.51%. As a group, equities research analysts predict that Vanda Pharmaceuticals Inc. will post -1.12 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets raised its stake in Vanda Pharmaceuticals by 1,184.6% during the third quarter. BNP Paribas Financial Markets now owns 62,238 shares of the biopharmaceutical company’s stock valued at $292,000 after buying an additional 57,393 shares during the last quarter. FMR LLC raised its stake in shares of Vanda Pharmaceuticals by 25.9% in the third quarter. FMR LLC now owns 149,739 shares of the biopharmaceutical company’s stock worth $702,000 after purchasing an additional 30,802 shares during the last quarter. Massachusetts Financial Services Co. MA purchased a new position in shares of Vanda Pharmaceuticals in the third quarter worth $864,000. GSA Capital Partners LLP purchased a new position in shares of Vanda Pharmaceuticals in the third quarter worth $143,000. Finally, Barclays PLC raised its stake in shares of Vanda Pharmaceuticals by 128.2% in the third quarter. Barclays PLC now owns 154,297 shares of the biopharmaceutical company’s stock worth $722,000 after purchasing an additional 86,677 shares during the last quarter. Hedge funds and other institutional investors own 88.14% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on VNDA shares. StockNews.com started coverage on Vanda Pharmaceuticals in a research note on Wednesday, February 5th. They issued a “hold” rating for the company. HC Wainwright raised their target price on Vanda Pharmaceuticals from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Tuesday, February 18th.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.